Login
Subscribe
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
pharmaceuticals, neuroscience
Independent FDA Advisory Panel Recommends Approving ALS Drug
Amanda Heidt | Sep 8, 2022 | 4 min read
The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.
How the Brain Changes on Ketamine: A Live Animal Study
Ruth Williams | Apr 11, 2019 | 3 min read
The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018 | 1 min read
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Teva Buys Mexican Pharma Firm
Bob Grant | Oct 5, 2015 | 1 min read
The Israeli drugmaker is purchasing the pharmaceutical company Rimsa for $2.3 billion.